• Isabelle Goyer, Edouard Lacotte, Julien Montreuil, Pascal Thibon, Anaïs R Briant, Claire Dupont, Jean-Jacques Parienti, and David Brossier.
• Department of Pharmacy, CHU de Caen, Caen, F-14000, France.
• Pediatr Crit Care Me. 2022 Dec 1; 23 (12): e590e594e590-e594.

ObjectivesWe aimed to evaluate the association between proton pump inhibitor (PPI) exposure and nosocomial infection (NI) during PICU stay.DesignPropensity score matched analysis of a single-center retrospective cohort from January 1, 2017, to December 31, 2018.SettingTertiary medical and surgical PICU in France.PatientsPatients younger than 18 years old, admitted to the PICU with a stay greater than 48 hours.InterventionPatients were retrospectively allocated into two groups and compared depending on whether they received a PPI or not.Measurements And Main ResultsSeven-hundred fifty-four patients were included of which 231 received a PPI (31%). PPIs were mostly used for stress ulcer prophylaxis (174/231; 75%), but upper gastrointestinal bleed risk factors were rarely present (18%). In the unadjusted analyses, the rate of NI was 8% in the PPI exposed group versus 2% in the nonexposed group. After propensity score matching ( n = 184 per group), we failed to identify an association between PPI exposure and greater odds of NI (adjusted odds ratio 2.9 [95% CI, 0.9-9.3]; p = 0.082). However, these data have not excluded the possibility that there is up to nine-fold greater odds of NI.ConclusionsThis study highlights the prevalent use of PPIs in the PICU, and the potential association between PPIs and nine-fold greater odds of NI is not excluded.Copyright © 2022 by the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.

13 keywords...

hide…